ARQ-234

ARQ-234 is a fusion protein biologic that acts as a highly selective and potent agonist of the CD200 receptor (CD200R). The drug is designed to modulate immune responses by activating CD200R, an immunological checkpoint receptor that restrains inflammatory immune activity and helps maintain immune tolerance. By binding to CD200R, ARQ-234 induces inhibitory signaling in immune cells, thereby restoring immune homeostasis and suppressing unwanted inflammation. This mechanism has shown promise in preclinical studies for atopic dermatitis, with evidence suggesting durable biological responses even after treatment discontinuation. The drug is being developed by Arcutis Biotherapeutics as a potential best-in-class therapy for atopic dermatitis[1][2][5][9].